TNF and early-onset autosomal dominant Alzheimer disease: By reducing cytokine production as well as decreasing microglial activation, siRNAs that target TNF-α or NLRP3 inflammasome components, for example, have shown significant effectiveness in preclinical models of Parkinson’s and Alzheimer’s diseases.